InMed Pharmaceuticals Completes 1-for-10 Reverse Stock Split; Trading Expected Nov. 5
Split-adjusted shares are expected to trade on Nasdaq under the existing INM symbol with a new CUSIP.
InMed Pharmaceuticals INM
InMed Pharmaceuticals Inc. · Nasdaq · Pharmaceutical Preparations
$13.21-24.51%close on Nov. 5, 2026 · volume 32K · Yahoo Finance
Price, last 53 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 23, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 4 | $1.32 | $5 |
| Oct. 19, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 1,086 | $1.32 | $1,434 |
| Oct. 16, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 1 | $1.32 | $1 |
| Oct. 15, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 984 | $1.32 | $1,301 |
| Oct. 14, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 8,021 | $1.33 | $10,668 |
| Oct. 13, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 564 | $1.33 | $750 |
| Oct. 8, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 2,256 | $1.33 | $2,997 |
| Oct. 7, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 3,046 | $1.33 | $4,051 |
| Oct. 6, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 5,601 | $1.33 | $7,436 |
| Oct. 5, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 18,182 | $1.33 | $24,182 |
| Oct. 2, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 8,307 | $1.33 | $11,048 |
| Oct. 1, 2026 | ADAR1 Capital Management LLC with Daniel Schneeberger 10% owner · indirect | Bought | 16,431 | $1.33 | $21,850 |
Latest 12 of 15. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 17 →Amendments to articles or bylaws; fiscal year change · Submission of matters to a vote of security holders · Other events · Financial statements and exhibits
AI summary, unreviewedInMed Pharmaceuticals (to be renamed Mentari Therapeutics) completes 1-for-10 reverse split and shareholder approval of Mentari merger; shares outstanding fall to about 549,374
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedInMed Pharmaceuticals Shareholders Approve Merger-Related Proposals, Name Change to Mentari Therapeutics, and 1-for-10 Share Consolidation
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedInMed Pharmaceuticals Reports Q1 Fiscal 2027 Net Loss of $2.3 Million; Cash Falls to $1.0 Million Amid Pending Mentari Merger and Nasdaq Equity Deficiency